PPARα agonist drugs inhibit proliferation, decrease invasiveness, and/or trigger apoptosis in cancer cell lines derived from breast, endometrial, lymphatic, central nervous system, and other malignancies [39–43]. The gene discussed is PPARA; the disease is cancer.